Neoadjuvant Chemoimmunotherapy for Resectable Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-analysis
Annals of Surgical Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 18, 2025
Language: Английский
Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment
Cancer Letters,
Journal Year:
2024,
Volume and Issue:
598, P. 217095 - 217095
Published: July 2, 2024
Language: Английский
The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer
Colum Dennehy,
No information about this author
Alisha F. Khan,
No information about this author
Ali H. Zaidi
No information about this author
et al.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(2), P. 286 - 286
Published: Jan. 9, 2024
Despite
advances
in
treatment
strategies
and
surgical
approaches
recent
years,
improving
survival
outcomes
esophagogastric
cancer
(EGC)
patients
treated
with
curative
intent
remains
a
significant
area
of
unmet
need.
The
emergence
adjuvant
immunotherapy
as
the
standard
care
for
resected
EGC
demonstrates
impact
recurrence-free
survival.
Neoadjuvant
perioperative
immunotherapies
represent
another
promising
approach
potential
advantages
over
therapy.
results
early
neoadjuvant
studies,
there
are
several
challenges
future
research
needs.
optimal
timing,
duration
number
doses
relation
to
surgery
combination
still
unclear.
In
addition,
rigorous
correlative
studies
need
be
performed
identify
biomarkers
patient
selection
response
prediction
maximize
benefits
immunotherapy.
this
review,
we
provide
concise
summary
current
resectable
discuss
rationale
use
immune
checkpoint
inhibitors
setting
pre-clinical
clinical
data
these
novel
therapies.
Finally,
will
examine
role
direction
paradigm
perceived
opportunities
that
lay
ahead.
Language: Английский
Budget impact analysis of neoadjuvant nivolumab for non-small cell lung cancer in the Chilean public healthcare system: An exploratory economic assessment
Clinical & Translational Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 2, 2025
Abstract
Purpose
Effective
and
sustainable
treatments
to
improve
patient
outcomes
are
urgently
needed
for
non-small
cell
lung
carcinoma
(NSCLC).
Neoadjuvant
therapies,
particularly
nivolumab,
have
shown
superior
in
event-free
survival
pathological
response,
yet
financial
coverage
is
scarce.
We
aim
provide
an
exploratory
economic
analysis
assess
the
implications
of
its
incorporation
into
routine
clinical
practice.
Methods
conducted
a
six-step
BIA
(budget
impact
analysis)
based
on
decision
tree
model
pathways,
probabilities,
resource
utilization
from
national
payer
perspective
at
(EFS)
horizon.
estimated
direct
cost
drugs
all
healthcare-related
services
two
scenarios:
baseline
scenario
[neoadjuvant
chemotherapy
(CT)]
alternative
nivolumab
combined
with
(N
+
CT)].
Results
The
funnel-down
technique
determined
359
eligible
patients
nationwide
per
year.
total
treatment
amounts
CLP
$
7315
million
Chilean
pesos
(€
8,063,219)
cohort,
three
top
drivers:
1L
after
recurrence
(51.98%),
resection
(29.33%)
2L
(5.85%).
amounted
6853
7,553,572),
highest
relative
expenditure
attributed
N
CT
scheme
(61.76%),
(31.31%),
follow-up
(2.73%).
Adjuvant
costs
decrease
1.03%,
as
does
(51.98%
versus
0.34%)
(5.85%
0.18%).
Early
intervention
NSCLC
reduces
budgetary
by
6.3%
(savings
−
462
509,647)
treated
cohort).
Conclusions
optimizes
healthcare
providing
access
therapies
that
rates
while
reducing
need
costly
advanced
stages.
This
approach
represents
dominant
strategy.
Language: Английский
Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma
Lei Xu,
No information about this author
Yunchun Long,
No information about this author
Yao Lü
No information about this author
et al.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: Dec. 16, 2024
The
RATIONALE-305
trial
demonstrated
that
tislelizumab
in
combination
with
chemotherapy
regimens
was
more
beneficial
than
alone
the
treatment
of
patients
advanced
gastric
cancer
or
gastroesophageal
junction
adenocarcinoma
(GC/GEJC).
This
study
aimed
to
evaluate
cost-effectiveness
GC/GEJC
from
perspective
Chinese
health
service
system.
Language: Английский
The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis
Bo Li,
No information about this author
Yujia Gu,
No information about this author
Weixing Zhao
No information about this author
et al.
Clinical & Translational Oncology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 9, 2024
Language: Английский
Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies
Cancers,
Journal Year:
2024,
Volume and Issue:
16(24), P. 4127 - 4127
Published: Dec. 10, 2024
Genitourinary
(GU)
malignancies
are
common
and
associated
with
significant
morbidity
mortality.
In
patients
localized
GU
cancers,
surgical
resection
or
definitive
radiation
remain
the
mainstays
of
treatment.
Despite
treatment,
many
high-risk
disease
experience
recurrence.
There
is
growing
interest
in
using
neoadjuvant
immunotherapy
to
improve
outcomes.
This
narrative
review
summarizes
current
evidence
for
cancers
including
renal
cell
carcinoma,
urothelial
prostate
cancer,
penile
squamous
testicular
germ
tumors.
We
also
discuss
ongoing
clinical
trials
candidate
biomarkers
optimize
patient
selection
treatment
Language: Английский